{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:55:30Z","timestamp":1787460930865,"version":"build-2736575974"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prp.2026.156463","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:11:06Z","timestamp":1775517066000},"page":"156463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Solid lipid nanoparticles in skin cancer: A comprehensive review of mechanism, formulation, and therapeutic advances"],"prefix":"10.1016","volume":"282","author":[{"given":"Krishil","family":"Oswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Tiwary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-2261","authenticated-orcid":false,"given":"Ryan","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6212","key":"10.1016\/j.prp.2026.156463_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1253735","article-title":"The melanoma revolution: from UV carcinogenesis to a new era in therapeutics","volume":"346","author":"Lo","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Invest Dermatol."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"21","key":"10.1016\/j.prp.2026.156463_bib4","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections\u2014United States, 1982\u20132030","volume":"64","author":"Guy","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib6","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.prp.2026.156463_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.635488","article-title":"Cutaneous melanoma classification: the importance of high-throughput genomic technologies","volume":"11","author":"Scatena","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib8","first-page":"2","article-title":"Melanoma\u2013clinical, dermatoscopical, and histopathological morphological characteristics","volume":"22","author":"\u0160itum","year":"2014","journal-title":"Acta Dermatovenerol. Croat."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2026.156463_bib10","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/cells10092320","article-title":"Molecular markers and targets in melanoma","volume":"10","author":"Teixido","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12943-023-01854-3","article-title":"Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches","volume":"22","author":"Hasan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12325-019-01130-1","article-title":"Recognising skin cancer in primary care","volume":"37","author":"Jones","year":"2020","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.prp.2026.156463_bib13","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.3390\/ijms140612222","article-title":"UV radiation and the skin","volume":"14","author":"D\u2019Orazio","year":"2013","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib14","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/bjc.1996.302","article-title":"Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study","volume":"73","author":"Bataille","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Coit","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"14","key":"10.1016\/j.prp.2026.156463_bib16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","article-title":"Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156463_bib17","first-page":"27","article-title":"UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer","author":"Liu-Smith","year":"2017","journal-title":"Ultra Light Hum. Heal Dis. Environ."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib18","first-page":"673","article-title":"Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: a concise review","volume":"22","author":"\u0160erman","year":"2022","journal-title":"Bosn. J. Basic Med Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/clinpract14010018","article-title":"A narrative review of current knowledge on cutaneous melanoma","volume":"14","author":"Caraban","year":"2024","journal-title":"Clin. Pr."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/cancers17040707","article-title":"Clinical approaches for the management of skin cancer: a review of current progress in diagnosis, treatment, and prognosis for patients with melanoma","volume":"17","author":"Connor","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/phpp.12770","article-title":"Prognostic biomarkers of cutaneous melanoma","volume":"38","author":"Ding","year":"2022","journal-title":"Photo Photo Photo"},{"issue":"11","key":"10.1016\/j.prp.2026.156463_bib22","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/ijms25115794","article-title":"Melanoma management: exploring staging, prognosis, and treatment innovations","volume":"25","author":"Shalata","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pathol.2023.11.004","article-title":"Prognostic and predictive biomarkers in melanoma","volume":"56","author":"Maher","year":"2024","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.prp.2026.156463_bib24","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.prp.2026.156463_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-022-01708-4","article-title":"Advancements in nanoparticle-based treatment approaches for skin cancer therapy","volume":"22","author":"Zeng","year":"2023","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib27","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"issue":"33","key":"10.1016\/j.prp.2026.156463_bib28","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156463_bib29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/medicina60060884","article-title":"Unaddressed challenges in the treatment of cutaneous melanoma?","volume":"60","author":"Villani","year":"2024","journal-title":"Medicina"},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib30","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.3390\/ijms23126388","article-title":"The treatment of advanced melanoma: therapeutic update","volume":"23","author":"Villani","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/14740338.2022.1986000","article-title":"Dermatologic adverse events associated with targeted therapies for melanoma","volume":"21","author":"Scarpato","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J. Immunol. Res"},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/ph17020214","article-title":"A review of current and pipeline drugs for treatment of melanoma","volume":"17","author":"Natarelli","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.prp.2026.156463_bib34","first-page":"747","article-title":"Novel Therapeutic Targets in Melanoma","volume":"15","author":"Cerezo","year":"2023"},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib35","article-title":"Curing stage IV melanoma: where have we been and where are we?","volume":"44","author":"Chan","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. B"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/biomedicines13010098","article-title":"Advances in cell and immune therapies for melanoma","volume":"13","author":"Timis","year":"2025","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/pharmaceutics17030296","article-title":"Advances in materials science for precision melanoma therapy: nanotechnology-enhanced drug delivery systems","volume":"17","author":"Moni","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100810","article-title":"Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments","volume":"30","author":"Souto","year":"2022","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1186\/s12885-022-09940-3","article-title":"Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156463_bib40","unstructured":"ME J.F., Siegel R.L., Isabelle Soerjomataram M.D., Ahmedin Jemal D.V.M. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, 2024."},{"issue":"14","key":"10.1016\/j.prp.2026.156463_bib41","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1002\/cam4.4046","article-title":"Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: an analysis of the global burden of disease study 2019","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib42","first-page":"331","article-title":"Non-melanoma skin cancer: carcinogenesis and chemoprevention","volume":"45","author":"Chen","year":"2013","journal-title":"Pathol. RCPA"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.6004\/jnccn.2016.0065","article-title":"Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Bichakjian","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0094-1298(20)32286-0","article-title":"Epidemiology of nonmelanoma skin cancer","volume":"24","author":"Strom","year":"1997","journal-title":"Clin. Plast. Surg."},{"key":"10.1016\/j.prp.2026.156463_bib45","series-title":"The Immunogenetics of Dermatologic Diseases","first-page":"397","article-title":"The immunogenetics of non-melanoma skin cancer","author":"Mushtaq","year":"2022"},{"issue":"11","key":"10.1016\/j.prp.2026.156463_bib46","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.clon.2019.08.009","article-title":"Current concepts in the surgical management of non-melanoma skin cancers","volume":"31","author":"Kosutic","year":"2019","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-022-00731-x","article-title":"Advances in topical treatments of cutaneous malignancies","volume":"24","author":"Algarin","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.det.2019.05.003","article-title":"Nonsurgical treatments for nonmelanoma skin cancer","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijwd.2019.05.005","article-title":"Management of keratinocyte carcinoma-Special considerations in the elderly","volume":"5","author":"Bailey","year":"2019","journal-title":"Int J. Women\u2019S. Dermatol."},{"issue":"9","key":"10.1016\/j.prp.2026.156463_bib50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3390\/cancers15092408","article-title":"The role of radiation therapy in the treatment of non-melanoma skin cancer","volume":"15","author":"Yosefof","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.det.2022.07.009","article-title":"Targeted therapy and immunotherapy in nonmelanoma skin cancer","volume":"41","author":"Aboul-Fettouh","year":"2023","journal-title":"Dermatol. Clin."},{"issue":"11","key":"10.1016\/j.prp.2026.156463_bib52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamainternmed.2013.639","article-title":"Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer","volume":"173","author":"Linos","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.prp.2026.156463_bib53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/978-0-387-77574-6_23","article-title":"Treatment of melanoma and nonmelanoma skin cancer","author":"Rass","year":"2008","journal-title":"Sunlight Vitam. D. Ski Cancer"},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib54","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3390\/cancers15123126","article-title":"Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies","volume":"15","author":"Plachouri","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004434","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer","volume":"10","author":"Silk","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156463_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2016.06.003","article-title":"Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?","volume":"27","author":"Blau","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.prp.2026.156463_bib57","article-title":"Solid lipid nanoparticles in imaging, diagnostics and theranostics: a review of a decade of innovations and clinical applications","author":"Tiwary","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2026.156463_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107086","article-title":"Biologics, theranostics, and personalized medicine in drug delivery systems","author":"Puccetti","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.prp.2026.156463_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-1-4939-9798-5_2","article-title":"Role of nanobiotechnology in drug delivery","author":"Jain","year":"2020","journal-title":"Drug Deliv. Syst."},{"key":"10.1016\/j.prp.2026.156463_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2021.100561","article-title":"Cubosomes in cancer drug delivery: a review","volume":"46","author":"Varghese","year":"2022","journal-title":"Colloid Interface Sci. Commun."},{"key":"10.1016\/j.prp.2026.156463_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2025.105510","article-title":"Solid lipid nanoparticles in the diagnosis and treatment of prostate cancer: a comprehensive review of two decades of advancements","author":"Tiwary","year":"2025","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.prp.2026.156463_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2021.100544","article-title":"Carbon nanotubes in COVID-19: a critical review and prospects","volume":"46","author":"Varghese","year":"2022","journal-title":"Colloid Interface Sci. Commun."},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib63","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3390\/pharmaceutics12121184","article-title":"Potential and applications of nanocarriers for efficient delivery of biopharmaceuticals","volume":"12","author":"Zeb","year":"2020","journal-title":"Pharmaceutics"},{"issue":"27","key":"10.1016\/j.prp.2026.156463_bib64","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2174\/1568026619666191024170212","article-title":"Nanoparticle delivery systems for DNA\/RNA and their potential applications in nanomedicine","volume":"19","author":"Shen","year":"2019","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.prp.2026.156463_bib65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2147\/DDDT.S439975","article-title":"A window for enhanced oral delivery of therapeutics via lipid nanoparticles","author":"Amekyeh","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1389203720666191202112429","article-title":"Nano-inspired technologies for peptide delivery","volume":"21","author":"Covarrubias-Zambrano","year":"2020","journal-title":"Curr. Protein Pept. Sci."},{"issue":"8","key":"10.1016\/j.prp.2026.156463_bib67","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.3390\/curroncol30080516","article-title":"Nanoparticle-based treatment approaches for skin cancer: a systematic review","volume":"30","author":"Diaz","year":"2023","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib68","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/nano9030474","article-title":"Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs","volume":"9","author":"Bay\u00f3n-Cordero","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2026.156463_bib69","doi-asserted-by":"crossref","DOI":"10.1039\/D5PM00109A","article-title":"Solid lipid nanoparticles in cervical cancer: a comprehensive review of a decade of progress and prospects","author":"Tiwary","year":"2025","journal-title":"RSC Pharm."},{"issue":"10","key":"10.1016\/j.prp.2026.156463_bib70","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2174\/1389200223666220416213639","article-title":"Receptor-mediated targeting in breast cancer through solid lipid nanoparticles and its mechanism","volume":"23","author":"Malik","year":"2022","journal-title":"Curr. Drug Metab."},{"issue":"37","key":"10.1016\/j.prp.2026.156463_bib71","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.2174\/1381612825666190903155321","article-title":"Solid lipid nanoparticles: a promising nanomaterial in drug delivery","volume":"25","author":"Rajpoot","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2026.156463_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2026.105574","article-title":"Lipid-based nanocarriers for antiviral drug delivery: a review of the advances, manufacturing technologies, therapeutic mechanisms, and clinical applications","author":"Maithania","year":"2026","journal-title":"Chem. Phys. Lipids"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib73","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/molecules27051543","article-title":"Perspectives and prospective on solid lipid nanoparticles as drug delivery systems","volume":"27","author":"Madkhali","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2026.156463_bib74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.colsurfb.2018.08.067","article-title":"Physicochemical characterization of solid lipid nanoparticles comprised of glycerol monostearate and bile salts","volume":"172","author":"Talele","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2026.156463_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.110184","article-title":"Preparation, characterization and in vitro cytotoxicity of fenofibrate and nabumetone loaded solid lipid nanoparticles","volume":"106","author":"Kumar","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"issue":"45","key":"10.1016\/j.prp.2026.156463_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903156","article-title":"On the structure of solid lipid nanoparticles","volume":"15","author":"Pink","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.prp.2026.156463_bib77","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2014.06.007","article-title":"Lipid nanoparticles: drug localization is substance-specific and achievable load depends on the size and physical state of the particles","volume":"189","author":"Kupetz","year":"2014","journal-title":"J. Control Release"},{"key":"10.1016\/j.prp.2026.156463_bib78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejpb.2017.03.010","article-title":"Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading","volume":"117","author":"Rosenblatt","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013drug release and release mechanism","volume":"45","author":"zur M\u00fchlen","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib80","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3109\/03639045.2014.909840","article-title":"Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations","volume":"40","author":"Kathe","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/pharmaceutics15030831","article-title":"Solid lipid nanoparticles: multitasking nano-carriers for cancer treatment","volume":"15","author":"German-Cort\u00e9s","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2017.08.004","article-title":"Carrier characteristics influence the kinetics of passive drug loading into lipid nanoemulsions","volume":"126","author":"G\u00f6ke","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.prp.2026.156463_bib83","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.msec.2012.04.017","article-title":"Optimizing SLN and NLC by 22 full factorial design: Effect of homogenization technique","volume":"32","author":"Severino","year":"2012","journal-title":"Mater. Sci. Eng. C."},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156463_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2014.05.024","article-title":"Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion","volume":"471","author":"Patil","year":"2014","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib85","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.msec.2016.05.119","article-title":"Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies","volume":"68","author":"Geszke-Moritz","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib86","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/138920012800166526","article-title":"Absorption, disposition and pharmacokinetics of solid lipid nanoparticles","volume":"13","author":"Qi","year":"2012","journal-title":"Curr. Drug Metab."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib87","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","article-title":"Elimination pathways of nanoparticles","volume":"13","author":"Poon","year":"2019","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res Pharm. Sci."},{"issue":"11","key":"10.1016\/j.prp.2026.156463_bib89","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12032-023-02184-6","article-title":"Recent advancement in targeted therapy and role of emerging technologies to treat cancer","volume":"40","author":"Barot","year":"2023","journal-title":"Med Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156463_bib90","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/cncr.34743","article-title":"Top advances of the year: precision oncology","volume":"129","author":"Desai","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2026.156463_bib91","article-title":"Innovations in cancer immunotherapy: a comprehensive overview of recent breakthroughs and future directions","author":"Hsu","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.14715\/cmb\/2024.70.5.13","article-title":"Recent advances in immunotherapy in cancer treatment","volume":"70","author":"Patel","year":"2024","journal-title":"Cell Mol. Biol."},{"key":"10.1016\/j.prp.2026.156463_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.830208","article-title":"Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib95","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib96","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1759-7714.15205","article-title":"Real-world survival outcomes of immunotherapy for advanced non-small cell lung cancer: a single-center retrospective review","volume":"15","author":"Punchhi","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib97","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.3390\/ijms24076199","article-title":"Solid lipid nanoparticles: applications and prospects in cancer treatment","volume":"24","author":"Sivadasan","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2026.156463_bib98","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/ar200011r","article-title":"Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring","volume":"44","author":"Namiki","year":"2011","journal-title":"Acc. Chem. Res"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib99","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/pharmaceutics15010216","article-title":"Lipid nanoparticles functionalized with antibodies for anticancer drug therapy","volume":"15","author":"Marques","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.colsurfb.2015.06.027","article-title":"Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin","volume":"134","author":"Jain","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2026.156463_bib101","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/IJN.S115136","article-title":"Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer","author":"Liu","year":"2017","journal-title":"Int J. Nanomed."},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib102","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/j.biomaterials.2011.01.048","article-title":"Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor","volume":"32","author":"Kuo","year":"2011","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib103","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/ph16070970","article-title":"Advances with lipid-based nanosystems for siRNA delivery to breast cancers","volume":"16","author":"Subhan","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.prp.2026.156463_bib104","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijpharm.2016.08.049","article-title":"Solid lipid nanoparticles co-loaded with doxorubicin and \u03b1-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models","volume":"512","author":"Oliveira","year":"2016","journal-title":"Int J. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib106","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/polym15030542","article-title":"Fabrication of sustained release curcumin-loaded solid lipid nanoparticles (cur-SLNs) as a potential drug delivery system for the treatment of lung cancer: optimization of formulation and in vitro biological evaluation","volume":"15","author":"Rahman","year":"2023","journal-title":"Polymers"},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156463_bib107","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijpharm.2012.03.032","article-title":"Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway","volume":"430","author":"Martins","year":"2012","journal-title":"Int J. Pharm."},{"issue":"10","key":"10.1016\/j.prp.2026.156463_bib108","first-page":"1897","article-title":"Glimpse into the cellular internalization and intracellular trafficking of lipid-based nanoparticles in cancer cells","volume":"22","author":"Kazemi","year":"2022","journal-title":"Anti-Cancer Agents Med Chem (Formerly Curr Med Chem Agents"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib109","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/adhm.201400675","article-title":"Targeting and microenvironment-responsive lipid nanocarrier for the enhancement of tumor cell recognition and therapeutic efficiency","volume":"4","author":"Gao","year":"2015","journal-title":"Adv. Health Mater."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib110","first-page":"372","article-title":"Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer","volume":"33","author":"Tupal","year":"2016","journal-title":"J. Micro"},{"key":"10.1016\/j.prp.2026.156463_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118609","article-title":"A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2\u2032, 2\u2032-difluorodeoxycytidine with increased solubility, stability, and antitumor activity","volume":"570","author":"Valdes","year":"2019","journal-title":"Int J. Pharm."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281004","article-title":"Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin Melanoma and squamous cell carcinoma","volume":"18","author":"Ali","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib113","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11095-021-03043-7","article-title":"Novel curcumin-resveratrol solid nanoparticles synergistically inhibit proliferation of melanoma cells","volume":"38","author":"Palliyage","year":"2021","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1166\/jbn.2012.1383","article-title":"Development of cationic solid lipid nanoparticles with factorial design-based studies for topical administration of doxorubicin","volume":"8","author":"Taveira","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.prp.2026.156463_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1102269","article-title":"Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry","volume":"13","author":"Bhattacharya","year":"2023","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/ijms19020255","article-title":"Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies","volume":"19","author":"Clemente","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib117","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/pharmaceutics15051375","article-title":"Solid lipid nanoparticles hydroquinone-based for the treatment of melanoma: efficacy and safety studies","volume":"15","author":"Trombino","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib118","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1080\/10717544.2017.1370619","article-title":"Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy","volume":"24","author":"Zhou","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.prp.2026.156463_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-021-00523-9","article-title":"High anticancer efficacy of solid lipid nanoparticles containing Zataria multiflora essential oil against breast cancer and melanoma cell lines","volume":"22","author":"Valizadeh","year":"2021","journal-title":"BMC Pharm. Toxicol."},{"key":"10.1016\/j.prp.2026.156463_bib120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.colsurfb.2016.11.043","article-title":"\u03b1-Tocopheryl linolenate solid lipid nanoparticles for the encapsulation, protection, and release of the omega-3 polyunsaturated fatty acid: In vitro anti-melanoma activity evaluation","volume":"151","author":"Cassano","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"20","key":"10.1016\/j.prp.2026.156463_bib121","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.3390\/nano12203547","article-title":"Development of new natural lipid-based nanoparticles loaded with aluminum-phthalocyanine for photodynamic therapy against melanoma","volume":"12","author":"Mello","year":"2022","journal-title":"Nanomaterials"},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156463_bib122","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2017.01.004","article-title":"Application of aluminum chloride phthalocyanine-loaded solid lipid nanoparticles for photodynamic inactivation of melanoma cells","volume":"518","author":"Goto","year":"2017","journal-title":"Int J. Pharm."},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib123","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1021\/acs.molpharmaceut.3c00280","article-title":"Dual-drug-loaded topical delivery of photodynamically active lipid-based formulation for combination therapy of cutaneous melanoma","volume":"20","author":"Jain","year":"2023","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7150\/thno.10804","article-title":"Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells","volume":"5","author":"Shen","year":"2015","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib125","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/C8BM01403E","article-title":"A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a murine melanoma model","volume":"7","author":"Banerjee","year":"2019","journal-title":"Biomater. Sci."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000354118","article-title":"Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate","volume":"27","author":"Ali-von Laue","year":"2014","journal-title":"Ski. Pharm. Physiol."},{"issue":"7","key":"10.1016\/j.prp.2026.156463_bib127","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/acs.molpharmaceut.3c01247","article-title":"Tumor cell membrane-encapsulated MLA solid lipid nanoparticles for targeted diagnosis and radiosensitization therapy of cutaneous squamous cell carcinoma","volume":"21","author":"Meng","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104720","article-title":"Sunscreens: a comprehensive review with the application of nanotechnology","author":"Chavda","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1467-2494.2001.00087.x","article-title":"A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles","volume":"23","author":"Wissing","year":"2001","journal-title":"Int J. Cosmet. Sci."},{"issue":"3","key":"10.1016\/j.prp.2026.156463_bib130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0168-3659(02)00056-1","article-title":"Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration","volume":"81","author":"Wissing","year":"2002","journal-title":"J. Control Release"},{"issue":"5","key":"10.1016\/j.prp.2026.156463_bib131","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1467-2494.2006.00320.x","article-title":"Sunblocking efficiency of various TiO2-loaded solid lipid nanoparticle formulations 1","volume":"28","author":"Cengiz","year":"2006","journal-title":"Int J. Cosmet. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib132","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00280-025-04848-8","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions","volume":"95","author":"Eltaib","year":"2025","journal-title":"Cancer Chemother. Pharm."},{"issue":"14","key":"10.1016\/j.prp.2026.156463_bib133","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305489","article-title":"Low-frequency ultrasound sensitive Piezo1 channels regulate keloid-related characteristics of fibroblasts","volume":"11","author":"Jiang","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib134","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/biom12020223","article-title":"A stepwise framework for the systematic development of lipid nanoparticles","volume":"12","author":"Basso","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.prp.2026.156463_bib135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2006.12.004","article-title":"Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization","volume":"67","author":"Attama","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2\u20133","key":"10.1016\/j.prp.2026.156463_bib136","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(99)00223-0","article-title":"Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties","volume":"66","author":"Jenning","year":"2000","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib137","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib138","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/689391","article-title":"Formulation optimization of erythromycin solid lipid nanocarrier using response surface methodology","volume":"2014","author":"Sahu","year":"2014","journal-title":"Biomed. Res Int"},{"issue":"8","key":"10.1016\/j.prp.2026.156463_bib139","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/03639045.2021.1989456","article-title":"Solid lipid nanoparticles by Venturi tube: preparation, characterization and optimization by Box\u2013Behnken design","volume":"47","author":"Garc\u00eda-Salazar","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib140","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1007\/s00216-017-0527-z","article-title":"Zeta potential: a case study of cationic, anionic, and neutral liposomes","volume":"409","author":"Smith","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"issue":"9","key":"10.1016\/j.prp.2026.156463_bib141","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/pharmaceutics14091798","article-title":"Quality by design-driven zeta potential optimisation study of liposomes with charge imparting membrane additives","volume":"14","author":"N\u00e9meth","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122014","article-title":"Design of nanostructured lipid carriers and solid lipid nanoparticles for enhanced cellular uptake","volume":"624","author":"Veider","year":"2022","journal-title":"Int J. Pharm."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib143","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/03639045.2010.501800","article-title":"Optimization of the emulsification and solvent displacement method for the preparation of solid lipid nanoparticles","volume":"37","author":"Noriega-Pel\u00e1ez","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib144","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejpb.2016.10.023","article-title":"The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN)","volume":"110","author":"Sznitowska","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.prp.2026.156463_bib145","first-page":"331","article-title":"Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations","volume":"59","author":"\u00dcner","year":"2004","journal-title":"Die Pharm. Int J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156463_bib146","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2010.12.036","article-title":"Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure","volume":"406","author":"Kovacevic","year":"2011","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib147","first-page":"1","article-title":"Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology","volume":"20","author":"Sarangi","year":"2018","journal-title":"Biomed. Micro"},{"issue":"12","key":"10.1016\/j.prp.2026.156463_bib148","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/pharmaceutics16121582","article-title":"Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect","volume":"16","author":"Feng","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib149","first-page":"1","article-title":"Advancement on nanoparticles-based approaches for the management of rheumatoid arthritis (RA): molecular mechanism, toxicity, and clinical perspectives","author":"Das","year":"2025","journal-title":"J. Drug Target"},{"key":"10.1016\/j.prp.2026.156463_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122753","article-title":"Lipid-based nanoparticles: enhanced cellular uptake via surface thiolation","volume":"635","author":"Knoll","year":"2023","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.prp.2026.156463_bib151","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2019.06.010","article-title":"vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends","volume":"142","author":"Berthelsen","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.prp.2026.156463_bib152","first-page":"539","article-title":"Solid lipid nanoparticles (SLN)\u2013effects of lipid composition on in vitro degradation and in vivo toxicity","volume":"61","author":"Weyhers","year":"2006","journal-title":"Die Pharm. Int J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.prp.2026.156463_bib153","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/17425247.2021.1921732","article-title":"Interdependency of influential parameters in therapeutic nanomedicine","volume":"18","author":"Kamali Shahri","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156463_bib154","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2016.12.040","article-title":"Microphase separation in solid lipid dosage forms as the cause of drug release instability","volume":"517","author":"Lopes","year":"2017","journal-title":"Int J. Pharm."},{"issue":"2","key":"10.1016\/j.prp.2026.156463_bib155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2005.06.004","article-title":"Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles","volume":"107","author":"Bunjes","year":"2005","journal-title":"J. Control Release"},{"issue":"24","key":"10.1016\/j.prp.2026.156463_bib156","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.1021\/acs.langmuir.5b00874","article-title":"Stability of the metastable \u03b1-polymorph in solid triglyceride drug-carrier nanoparticles","volume":"31","author":"Joseph","year":"2015","journal-title":"Langmuir"},{"key":"10.1016\/j.prp.2026.156463_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.07.002","article-title":"Role of particle size in translational research of nanomedicines for successful drug delivery: Discrepancies and inadequacies","author":"Chan","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.prp.2026.156463_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121246","article-title":"Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells","volume":"610","author":"Arduino","year":"2021","journal-title":"Int J. Pharm."},{"issue":"9","key":"10.1016\/j.prp.2026.156463_bib159","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/pharmaceutics14091886","article-title":"Review on the scale-up methods for the preparation of solid lipid nanoparticles","volume":"14","author":"Khairnar","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156463_bib160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jconrel.2024.07.021","article-title":"Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends","volume":"373","author":"Biscaia-Caleiras","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.prp.2026.156463_bib161","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carbpol.2014.12.084","article-title":"Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake","volume":"122","author":"Luo","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.prp.2026.156463_bib162","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actbio.2023.05.043","article-title":"Overcoming tumor microenvironment obstacles: current approaches for boosting nanodrug delivery","volume":"166","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.prp.2026.156463_bib163","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2021.11.024","article-title":"Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles","volume":"341","author":"Souri","year":"2022","journal-title":"J. Control Release"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:36:59Z","timestamp":1785508619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":163,"alternative-id":["S0344033826001159"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156463","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solid lipid nanoparticles in skin cancer: A comprehensive review of mechanism, formulation, and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156463"}}